These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28167482)

  • 21. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.
    Jackson EK; Mi Z; Tofovic SP; Gillespie DG
    Hypertension; 2015 Jan; 65(1):238-49. PubMed ID: 25368027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of antihypertensive therapy on serum lipids in newly diagnosed essential hypertensive men.
    Nandeesha H; Pavithran P; Madanmohan T
    Angiology; 2009; 60(2):217-20. PubMed ID: 18445617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies.
    Rückert IM; Schunk M; Holle R; Schipf S; Völzke H; Kluttig A; Greiser KH; Berger K; Müller G; Ellert U; Neuhauser H; Rathmann W; Tamayo T; Moebus S; Andrich S; Meisinger C
    Cardiovasc Diabetol; 2012 May; 11():50. PubMed ID: 22569118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular risk factor control is insufficient in young patients with coronary artery disease.
    Christiansen MK; Jensen JM; Brøndberg AK; Bøtker HE; Jensen HK
    Vasc Health Risk Manag; 2016; 12():219-27. PubMed ID: 27307744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.
    Valensi P; de Pouvourville G; Benard N; Chanut-Vogel C; Kempf C; Eymard E; Moisan C; Dallongeville J
    Diabetes Metab; 2015 Jun; 41(3):231-8. PubMed ID: 25976701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile.
    Heald AH; Knapman H; Nair S; Chambers T; Radford D; Rushton T; Anderson SG
    Prim Care Diabetes; 2012 Oct; 6(3):213-9. PubMed ID: 22560663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The MAURO study: baseline characteristics and compliance with guidelines targets.
    Leonardis D; Mallamaci F; Enia G; Postorino M; Tripepi G; Zoccali C;
    J Nephrol; 2012; 25(6):1081-90. PubMed ID: 23172127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain.
    Barrios V; Escobar C; Calderón A; Llisterri JL; Echarri R; Alegría E; Muñiz J; Matalí A
    J Clin Hypertens (Greenwich); 2007 May; 9(5):324-9. PubMed ID: 17485967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia.
    Chopra I; Kamal KM
    Hosp Pract (1995); 2014 Apr; 42(2):77-88. PubMed ID: 24769787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
    Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
    Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of co-morbid mental illness on the diagnosis and management of patients hospitalized for medical conditions in a general hospital.
    Briskman I; Bar G; Boaz M; Shargorodsky M
    Int J Psychiatry Med; 2012; 43(4):339-48. PubMed ID: 23094466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.
    Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC
    Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of vascular risk factors in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST).
    Meschia JF; Voeks JH; Leimgruber PP; Mantese VA; Timaran CH; Chiu D; Demaerschalk BM; Howard VJ; Hughes SE; Longbottom M; Howard AG; Brott TG
    J Am Heart Assoc; 2014 Nov; 3(6):e001180. PubMed ID: 25428209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.
    Lynch M; Ahern TB; Timoney I; Sweeney C; Kelly G; Hughes R; Tobin AM; O'Shea D; Kirby B
    Trials; 2016 Jan; 17():29. PubMed ID: 26767505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personal attributes that influence the adequate management of hypertension and dyslipidemia in patients with type 2 diabetes. Results from the DIAB-CORE Cooperation.
    Rückert IM; Maier W; Mielck A; Schipf S; Völzke H; Kluttig A; Greiser KH; Berger K; Müller G; Ellert U; Neuhauser H; Rathmann W; Tamayo T; Moebus S; Andrich S; Meisinger C
    Cardiovasc Diabetol; 2012 Oct; 11():120. PubMed ID: 23035799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of spirulina on weight loss and blood lipids: a review.
    DiNicolantonio JJ; Bhat AG; OKeefe J
    Open Heart; 2020; 7(1):e001003. PubMed ID: 32201580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension.
    Mazza A; Schiavon L; Rigatelli G; Torin G; Lenti S
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):345-350. PubMed ID: 31352663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.